Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

2010 ◽  
Vol 123 (2) ◽  
pp. 427-435 ◽  
Author(s):  
Christopher Lobo ◽  
Gilberto Lopes ◽  
Odalys Baez ◽  
Aurelio Castrellon ◽  
Annapoorna Ferrell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

BMC Cancer ◽  
2005 ◽  
Vol 5 (1) ◽  
Author(s):  
Djelila Allouache ◽  
Sulochana R Gawande ◽  
Michele Tubiana-Hulin ◽  
Nicole Tubiana-Mathieu ◽  
Sophie Piperno-Neumann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent

scholarly journals Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

2006 ◽  
Vol 94 (11) ◽  
pp. 1604-1609 ◽  
Author(s):  
F Ciardiello ◽  
T Troiani ◽  
F Caputo ◽  
M De Laurentiis ◽  
G Tortora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document